Bank Of New York Mellon Corp Curis Inc Transaction History

Bank Of New York Mellon Corp

  • $538 Trillion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
BUY
$0.51 - $0.78 $39,884 - $60,999
78,204 New
78,204 $46.6 Million
Q4 2022

Feb 14, 2023
BUY
$0.47 - $17.22 $36,755 - $1.35 Million
78,204 New
78,204 $43,000
Q2 2022

Aug 15, 2022
SELL
$0.71 - $2.43 $170,377 - $583,122
-239,968 Reduced 75.36%
78,470 $77,000
Q1 2022

May 11, 2022
SELL
$2.31 - $5.13 $6,699 - $14,877
-2,900 Reduced 0.9%
318,438 $757,000
Q4 2021

Feb 11, 2022
SELL
$4.45 - $8.09 $28,101 - $51,088
-6,315 Reduced 1.93%
321,338 $1.53 Million
Q3 2021

Nov 12, 2021
BUY
$6.94 - $8.85 $456,159 - $581,701
65,729 Added 25.09%
327,653 $2.57 Million
Q2 2021

Aug 11, 2021
BUY
$7.45 - $16.27 $1.39 Million - $3.05 Million
187,202 Added 250.53%
261,924 $2.11 Million
Q1 2021

May 13, 2021
SELL
$8.78 - $12.8 $26,524 - $38,668
-3,021 Reduced 3.89%
74,722 $845,000
Q4 2020

Feb 09, 2021
BUY
$1.08 - $8.2 $15,184 - $115,291
14,060 Added 22.08%
77,743 $636,000
Q3 2020

Nov 12, 2020
BUY
$0.95 - $1.42 $0 - $1
1 Added 0.0%
63,683 $74,000
Q2 2020

Aug 12, 2020
BUY
$0.63 - $1.7 $0 - $1
1 Added 0.0%
63,682 $77,000
Q1 2020

May 06, 2020
SELL
$0.67 - $1.85 $417 - $1,152
-623 Reduced 0.97%
63,681 $44,000
Q2 2019

Aug 12, 2019
BUY
$1.36 - $2.35 $4 - $7
3 Added 0.0%
64,304 $120,000
Q1 2019

May 14, 2019
SELL
$0.78 - $2.01 $1,783 - $4,596
-2,287 Reduced 3.43%
64,301 $128,000
Q4 2018

Feb 11, 2019
BUY
$0.62 - $2.25 $27,371 - $99,330
44,147 Added 196.72%
66,588 $46,000
Q3 2018

Nov 09, 2018
SELL
$1.38 - $1.94 $1 - $1
-1 Reduced -0.0%
22,441 $0
Q2 2018

Aug 06, 2018
BUY
$1.73 - $3.35 $38,824 - $75,180
22,442 New
22,442 $38,000

About CURIS INC

CRIS Quotes by TradingView
  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $409M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email